Use of Tocilizumab in hospitalized patients during the first wave of the COVID-19 pandemic
DOI:
https://doi.org/10.30827/ars.v63i2.22348Keywords:
Tocilizumab, COVID-19, cohort studyAbstract
Introduction: The aim of this study was to characterize the use of tocilizumab in a hospital.
Method: Retrospective cohort study including adult SARS-CoV-2 infected inpatients with moderately severe infection (PaO2/FiO2 < 300). ORs for mortality and treatment success were calculated.
Results: The tocilizumab group (n=18), presented 5 days of symptoms vs 7 days in the untreated group (n=71). Minimum PaO2/FiO2 was 147.5 (95%CI: 116.7 to 194.0) vs 255.6 (95%CI: 320.7 to 452.4) (p=0.01).
No significant differences were found between the two groups concerning survival (OR=1.22; 95%CI: 0.38 to 3.92), nor treatment success (OR=0.46; 95%CI: 0.16 to 1.33). After adjusting for age, sex and total corticosteroid dose, OR for success was 0.18 (95%CI: 0.03 to 0.96), while mortality was not significant.
Conclusions: The use of tocilizumab in moderately severe hospitalized patients could decrease the hyperinflammatory state preventing disease progression.
Downloads
References
Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation. 2020 ;39(5):405-7
Shetty A, Hanson R, Korsten P, Shawagfeh M, Arami S, Volkov S, et al. Tocilizumab in the treatment of rheumatoid arthritis and beyond. Drug design, development and therapy. 2014;8:349-64.
Alvarez-Arroyo L, Carrera-Hueso FJ, El-Qutob D, Robustillo-Villarino M, Girona-Sanz AM, Pin-Godos MT. Estudio descriptivo de una cohorte de pacientes COVID 19 hospitalizados en España. Gac Med Mex. 2021;157(1):76-83
Melegari G, Giuliani E, Dallai C, Veronesi L, Bertellini E, Osmenaj S, Barbieri A. Intensive Care Patients from the First COVID-19 Wave: One-Year Survival after Tocilizumab Treatment. J Pers Med. 2021;11(11):1234. doi: 10.3390/jpm11111234.
Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S et al.Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med. 2021;384(16):1503-1516.
The REMAP-CAP investigators, interleukin-6 receptor antagonist in critically ill patients with covid-19. N Engl J Med.2021;384:1491-1502.
Duarte-Millán MA, Mesa-Plaza N, Guerrero-Santillán M, Morales-Ortega A, Bernal-Bello D, Farfán-Sedano AI et al. Prognostic factors and combined use of tocilizumab and corticosteroids in a Spanish cohort of elderly COVID-19 patients. J Med Virol. 2021 Nov 29. doi: 10.1002/jmv.27488.
Mushtaq MZ, Mahmood SBZ, Almas A, Ather Wasti S, Ahsan Ali S. Tocilizumab in critically ill COVID-19 patients: An observational study. Int Immunopharmacol. 2021 Nov 20:108384. doi: 10.1016/j.intimp.2021.108384.
Luo L, Luo T, Du M, Mei H, Hu Y. Efficacy and safety of tocilizumab in hospitalized COVID-19 patients: a systematic review and meta-analysis. J Infect. 2021:S0163-4453(21)00557-0.
Ortiz Pérez S, Caro Teller JM, García Muñoz C, Herraiz Robles P, Lozano Morillo F, Pablos Álvarez JL, Ferrari Piquero JM. Suministro controlado de tocilizumab durante la pandemia de COVID-19 e influencia sobre el tratamiento de pacientes reumatológicos. Rev Esp Salud Publica. 2021;95:e202111109.
Albertini L, Soletchnik M, Razurel A, Cohen J, Bidegain F, Fauvelle F, et al. Observational study on off-label use of tocilizumab in patients with severe COVID-19. Eur J Hosp Pharm. 2021;28(1):22-7.
RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637-1645.
Levi M. Tocilizumab in severe COVID-19: A promise fulfilled. Eur J Intern Med. 2021 Nov 22:S0953-6205(21)00390-3. doi: 10.1016/j.ejim.2021.11.015.
Águas R, Mahdi A, Shretta R, Horby P, Landray M, White L, et al. Potential health and economic impacts of dexamethasone treatment for patients with COVID-19. Nat Commun. 2021;12(1):915
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 LAURA ALVAREZ ARROYO
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
